Related Experiment Videos
Role of transthoracic echocardiography in atrial fibrillation
1Division of Cardiology, Hennepin County Medical Center, 701 Park Avenue South, Minneapolis, MN 55415, USA.
Insights
Atrial fibrillation management is complex. Transthoracic echocardiography and clinical features help guide therapy, assess risks for stroke, and manage complications in this common heart condition.
Area of Science:
- Cardiology
- Medical Imaging
Background:
- Atrial fibrillation (AF) is a growing clinical challenge, particularly with an aging population.
- Managing AF involves complex strategies for rate control, rhythm conversion, maintenance of sinus rhythm, and thromboembolism prevention.
Purpose of the Study:
- To highlight the importance of clinical and transthoracic echocardiography (TTE) features in managing atrial fibrillation.
- To discuss the role of TTE in risk stratification for thromboembolism and guiding therapeutic decisions.
Main Methods:
- Review of clinical and echocardiographic predictors of atrial fibrillation development and management.
- Analysis of risk factors for thromboembolism and hemorrhagic complications in AF patients.
- Emphasis on the utility of transthoracic echocardiography for noninvasive cardiac assessment.
Main Results:
- Left atrial size, left ventricular wall thickness, and function predict AF risk.
- In nonvalvular AF, duration is key; in others, left atrial size predicts cardioversion success.
- TTE aids in evaluating left ventricular function and identifying high-risk features like valvular disease and hypertrophic cardiomyopathy.
Conclusions:
- Integrating clinical and TTE findings is crucial for effective AF management and risk stratification.
- TTE provides essential noninvasive data to guide treatment strategies and patient risk assessment.
- Accurate risk stratification is vital for balancing anticoagulation benefits against bleeding risks in AF patients.
Abstract:
Atrial fibrillation is a major clinical problem that is predicted to be encountered more frequently as the population ages. The clinical management of atrial fibrillation has become increasingly complex as new therapies and strategies have become available for ventricular rate control, conversion to sinus rhythm, maintenance of sinus rhythm, and prevention of thromboembolism. Clinical and transthoracic echocardiographic features are important in determining etiology and directing therapy for atrial fibrillation. Left atrial size, left ventricular wall thickness, and left ventricular function have independent predictive value for determining the risk of developing atrial fibrillation. Left atrial size may have predictive value in determining the success of cardioversion and maintaining sinus rhythm in selected clinical settings but has less value in the most frequently encountered group, patients with nonvalvular atrial fibrillation, in whom the duration of atrial fibrillation is the most important feature. When selecting pharmacological agents to control ventricular rate, convert to sinus rhythm, and maintain normal sinus rhythm, transthoracic echocardiography (TTE) allows noninvasive evaluation of left ventricular function and hence guides management. The combination of clinical and transthoracic echocardiographic features also allows risk stratification for thromboembolism and hemorrhagic complications in atrial fibrillation. High-risk clinical features for thromboembolism supported by epidemiological observations, results of randomized clinical trials, and meta-analyses include rheumatic valvular heart disease, prior thromboembolism, congestive heart failure, hypertension, older (> 75 years old) women, and diabetes. Small series of cases also suggest those with hyperthyroidism and hypertrophic cardiomyopathy are at high risk. TTE plays a unique role in confirming or discovering high-risk features such as rheumatic valvular disease, hypertrophic cardiomyopathy, and decreased left ventricular function. Validation of the risk stratification scheme used in the Stroke Prevention in Atrial Fibrillation-III trial is welcomed by clinicians who are faced daily with balancing the benefit and risks of anticoagulation to prevent thromboembolism in patients with atrial fibrillation.